Last reviewed · How we verify
NCT04806763: MCOS
Myopia Control With Orthokeratology Contact Lenses in Spain
NA trial testing Menicon Z Night in Myopia, Progressive in 69 participants. Completed in 1 March 2010.
1 March 2010
Quick facts
| Lead sponsor | Menicon Co., Ltd. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 69 |
| Start date | 1 March 2007 |
| Primary completion | 1 March 2010 |
| Estimated completion | 1 March 2010 |
Drugs / interventions tested
- Menicon Z Night
- Control
Conditions studied
- Myopia, Progressive — all drugs for Myopia, Progressive →
- Children, Only — all drugs for Children, Only →
- Contact Lens Complication — all drugs for Contact Lens Complication →
- Perception, Self — all drugs for Perception, Self →
Sponsor
Menicon Co., Ltd.
Who can join
Adults 6 to 12, any sex, with Myopia, Progressive or Children, Only. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this prospective study is to assess the efficacy, safety and patient-reported outcomes of the Menicon Z Night orthokeratolgy contact lens for reducing myopia progression in children.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04806763
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Menicon Z Night
Trials testing the same drug.
- NCT04806698 — Long-term Efficacy of Orthokeratology Contact Lens Wear in Controlling the Progression of Childhood Myopia · NA · completed
- NCT04806711 — Eleven Years of Menicon Z Night Contact Lens Wear in Reducing Myopia Progression in Children · NA · completed
Other recruiting trials for Myopia, Progressive
Currently open trials in the same condition.
- NCT06927388 — Myopia Progression With Freeform Myopia Control Spectacles · NA · active not recruiting
- NCT07055815 — Impact of Digital Screen Time in Progression of Myopia in Children · active not recruiting
- NCT06389110 — Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elo · Phase 3 · recruiting
- NCT06647160 — Safety and Efficacy of Blue Star MAX-5 Lenses in Myopia Control · NA · active not recruiting
- NCT06520124 — Stellest Lens Wear in Adult Progressing Myopes · NA · active not recruiting
Other Menicon Co., Ltd. trials
Trials by the same sponsor.
- NCT07345416 — A Clinical Trial Assessing the Efficacy and Safety of ST-1 Silicone Hydrogel Daily Disposable Soft Contact Lenses Compar · NA · not yet recruiting
- NCT07047924 — A Clinical Trial Assessing the Safety and Effectiveness of Orthokeratology Lenses in Patients With Myopia and Myopic Ast · NA · not yet recruiting
- NCT06037850 — Clinical Trial of Orthokeratology Lens (MCOK-01) · NA · completed
- NCT04299243 — Clinical Trial Protocol for Safety and Efficacy of Soft Contact Lens · NA · completed
- NCT03454542 — Assessment of Comfort & Ocular Surface Parameters w Novel Designs of Daily Disposable Silicone Hydrogel Contact Lenses · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04806763 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Menicon Co., Ltd.
- Last refreshed: 26 March 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04806763.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing